- Poster presentation
- Open Access
Bardet-Biedl and Alström syndromes in Spain
© Valverde et al; licensee BioMed Central Ltd. 2012
- Published: 16 November 2012
- Genetic Counselling
- Molecular Function
- Direct Sequencing
- Major Gene
- Heterogeneous Nature
Bardet-Biedl (BBS, OMIM 209900) and Alström (AS, OMIM #203800) syndromes belong to a group of heterogenic disorders called ciliopathies where alterations on the cilia and the ciliary mechanisms are implicated. The genetically heterogeneous nature of BBS, with fifteen genes identified (BBS1-BBS15) to date, is also shown in the considerable inter- and intra-familial variation in the phenotype. Mutation screening of the involved genes has resulted in the identification of approximately 70% of the causative mutations, indicating that additional BBS genes have to be identified. ALMS1 is the only gene associated with the development of AS. ALMS1 encodes a novel protein, widely expressed and with unknown molecular function. We recruited 81 BBS families with 105 affected patients (44 females/ 61 males) and 5 AS families with 5 patients (4 females/ 1 male). Molecular analysis was performed using three strategies: homozygosity mapping when the family was consanguineous, BBS genotyping chip (Asper Ohthalmics), and direct sequencing. We were able to detected at least one mutation in 47% of the BBS patients. The allelic implication for the major genes in our patients was as follows: BBS1 (56%), BBS10 (20%), BBS12 (11%), BBS6 (7%), BBS3 (4%), BBS2 (1%) and BBS5 (1%). In AS patients we could detect the two responsible mutations in two families, and only one mutation in heterozygous state in a third family. The molecular study of these syndromes can be very helpful in providing a diagnosis in this patients, hence appropriate genetic counselling for families and adequate medical follow-up for affected children.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.